



## LJMU Research Online

Brie, D, Sahebkar, A, Penson, P, Dinca, M, Ursoniu, S, Serban, M-C, Zanchetti, A, Howard, G, Ahmed, A, Aronow, WS, Muntner, P, Lip, GYH, Wong, ND, Rysz, J and Banach, M

**Effects of Pentoxifylline on Inflammatory Markers and Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials**

<http://researchonline.ljmu.ac.uk/3945/>

### Article

**Citation** (please note it is advisable to refer to the publisher's version if you intend to cite from this work)

**Brie, D, Sahebkar, A, Penson, P, Dinca, M, Ursoniu, S, Serban, M-C, Zanchetti, A, Howard, G, Ahmed, A, Aronow, WS, Muntner, P, Lip, GYH, Wong, ND, Rysz, J and Banach, M (2016) Effects of Pentoxifylline on Inflammatory Markers and Blood Pressure: A Systematic Review and Meta-**


LJMU has developed **LJMU Research Online** for users to access the research output of the University more effectively. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain.

The version presented here may differ from the published version or from the version of the record. Please see the repository URL above for details on accessing the published version and note that access may require a subscription.

For more information please contact [researchonline@ljmu.ac.uk](mailto:researchonline@ljmu.ac.uk)

<http://researchonline.ljmu.ac.uk/>





## Effects of Pentoxifylline on Inflammatory Markers and Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

*Short Title: Pentoxifylline & Inflammatory Markers*

Daniel BRIE<sup>a§</sup>, Amirhossein SAHEBKAR<sup>b,c§</sup>, Peter E. Penson<sup>d</sup> Madalina DINCA<sup>e</sup>, Sorin URSONIU<sup>f</sup>, Maria-Corina SERBAN<sup>g,h</sup>, Alberto ZANCHETTI<sup>i</sup>, George HOWARD<sup>j</sup>, Ali AHMED<sup>k</sup>, Wilbert S. ARONOW<sup>l</sup>, Paul MUNTNER<sup>§</sup>, Gregory Y.H. LIP<sup>m</sup>, Nathan WONG<sup>n</sup>, Jacek RYSZ<sup>o</sup>, Maciej BANACH<sup>p\*</sup>

*Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group*

<sup>a</sup>Institute for Cardiovascular Medicine Timisoara, Cardiology Department, University of Medicine and Pharmacy “Victor Babes”, Timisoara, Romania; <sup>b</sup>Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; <sup>c</sup>Metabolic Research Centre, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Australia; <sup>d</sup>School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University; <sup>e</sup>Independent Pharmacist Researcher, Leuven, Belgium; <sup>f</sup>Department of Functional Sciences, Discipline of Public Health, “Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania; <sup>g</sup>Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA; <sup>h</sup>Department of Functional Sciences, Discipline of Pathophysiology, “Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania; <sup>i</sup>Istituto Auxologico Italiano and University of Milan, Milan, Italy; <sup>j</sup>Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, USA; <sup>k</sup>Veterans Affairs Medical Center, Washington, DC <sup>l</sup>Department of Medicine, New York Medical College, Valhalla, NY, USA; <sup>m</sup>University of Birmingham

Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK; <sup>n</sup>University of California, Division of Cardiology, Heart Disease Prevention Program, Irvine, CA, USA; <sup>o</sup>Chair of Nephrology and Hypertension, Medical University of Lodz, Poland; <sup>p</sup>Department of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz, Poland.

\$ Dr Brie and Dr Sahebkar contributed equally to this work.

**\*Corresponding author:** Prof. Maciej Banach, MD, PhD, FNLA, FAHA, FESC; FASA, Head, Department of Hypertension, WAM University Hospital in Lodz, Medical University of Lodz, Zeromskiego 113; 90-549 Lodz, Poland. **Phone:** +48 42 639 37 71; **Fax:** +48 42 639 37 71; **E-mail:** [maciejbanach@aol.co.uk](mailto:maciejbanach@aol.co.uk)

#### **Conflicts of Interest and Source of Funding**

This work was produced without any specific funding. The authors do not have any conflicts of interest to declare

**Word count (including references, but not tables and legends): 5336**

**Number of tables: 2**

**Number of figures: 8**

**Number of supplementary digital content files: 0**

## Abstract

**Introduction:** Pentoxifylline is a xanthine derivative with potential cardiovascular benefits.

**Aim:** To evaluate the impact of pentoxifylline on blood pressure and plasma tumor necrosis factor- $\alpha$ , C-reactive protein and interleukin-6 through a systematic review and meta-analysis of randomized controlled trials.

**Methods:** The protocol was registered (PROSPERO: CRD42016035988). The search included PUBMED, ProQuest, Scopus, and EMBASE until September 1<sup>st</sup> 2015 to identify trials reporting blood pressure or inflammatory markers during pentoxifylline therapy. Quantitative data synthesis was performed using a random-effects model, with weighted mean difference and 95% confidence intervals as summary statistics.

**Results:** 15 studies (16 treatment arms) were found to be eligible for inclusion. Meta-analysis did not suggest any effect of pentoxifylline on either systolic or diastolic blood pressure. Pentoxifylline treatment was associated with a significant reduction in plasma concentrations of tumor necrosis factor- $\alpha$  (weighted mean difference: -1.03 pg/mL, 95% confidence interval: -1.54, -0.51,  $p < 0.001$ , 11 treatment arms) and C-reactive protein (weighted mean difference: -1.39 mg/L, 95% confidence interval: -2.68, -0.10,  $p = 0.034$ , 5 treatment arms). No alteration in plasma interleukin-6 concentration was observed. The impact of pentoxifylline on plasma tumor necrosis factor- $\alpha$  levels was found to be positively associated with treatment duration (slope: 0.031; 95% confidence interval: 0.004, 0.057;  $p = 0.023$ ) but independent of pentoxifylline dose (slope: -0.0003; 95% confidence interval: -0.002, 0.001;  $p = 0.687$ ).

**Conclusions:** Pentoxifylline did not alter blood pressure or plasma interleukin-6 concentration, but significantly reduced circulating tumor necrosis factor- $\alpha$  and C-reactive protein concentrations.

**Keywords:** pentoxifylline, C reactive protein, interleukin-6, TNF- $\alpha$ , blood pressure.

**No. of words: 242**

### **Condensed abstract**

Pentoxifylline is a xanthine derivative with potential cardiovascular benefits. This study evaluated the impact of pentoxifylline on blood pressure, plasma tumor necrosis factor- $\alpha$ , C-reactive protein and interleukin-6 through a systematic review and meta-analysis of randomized controlled trials. No effect of pentoxifylline on either systolic or diastolic blood pressure or interleukin-6 was observed. Pentoxifylline treatment was associated with a statistically significant reduction in plasma concentrations of tumor necrosis factor- $\alpha$  and C-reactive protein. The impact of pentoxifylline on plasma tumor necrosis factor- $\alpha$  levels was found to be positively associated with treatment duration but independent of pentoxifylline dose.

**No. of words: 95**

### **INTRODUCTION**

Pentoxifylline is a methylxanthine derivative and a non-selective phosphodiesterase inhibitor with hemorheological activity. Its primary use is for treating the symptoms of claudication, a manifestation of peripheral artery disease which results

in muscle pain [1]. In common with other methylxanthines such as theobromine, aminophylline, theophylline and caffeine, many of the pharmacological activities of pentoxifylline can be explained by inhibition of phosphodiesterases [2]. This group of enzymes is responsible for the breakdown of the intracellular second-messengers, cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). Thus the methylxanthines increase intracellular concentrations of cAMP and cGMP in a wide variety of tissues [2]. Pentoxifylline increases erythrocyte flexibility, reduces blood viscosity, increases microcirculatory flow and tissue perfusion and decreases the potential for platelet aggregation and thrombus formation [3, 4]. It has been reported that pentoxifylline might also influence the function of immune cells and the production of cytokines [5, 6]. Interleukin (IL)-1 and tumor necrosis factor-alpha (TNF- $\alpha$ ) are pro-inflammatory cytokines involved in inflammatory diseases in humans including rheumatoid arthritis, inflammatory bowel disease, graft-vs-host disease and many others. Administration of these inflammatory cytokines in humans results in fever, inflammation, tissue destruction, and, in some cases, shock and death [7]. Reduction of the biological activities of IL-1, TNF- $\alpha$  and other inflammatory cytokines is an important target for the treatment of many pathologies. C-Reactive Protein (CRP) is a marker of systemic inflammation and is useful in cardiovascular risk prediction [8, 9]. The increasing recognition of the role of inflammation in atherosclerosis, has led to the development and testing of anti-inflammatory agents for the prevention of cardiovascular events [10].

Experimental and animal studies have shown that pentoxifylline administration causes immune modulation in a dose-dependent manner. This is exemplified by increased leukocyte deformability and chemotaxis, decreased endothelial leukocyte

adhesion, neutrophil degranulation, TNF- $\alpha$  production and NK cell activity [5, 11, 12]. Moreover, pentoxifylline is able to suppress the synthesis of TNF- $\alpha$  in cell cultures, and *in vivo*, and to protect experimental animals against endotoxin shock [13]. At high concentrations, pentoxifylline has been shown to suppress TNF- $\alpha$  production by stimulating alveolar macrophages. However, in the same study, pentoxifylline did not affect the production of IL-1 $\beta$ , IL-6 or GM-CSF. In peripheral blood monocyte cultures it inhibited the production of TNF- $\alpha$  and GM-CSF, at all concentrations which were tested [14].

Phosphodiesterase inhibitors such as pentoxifylline cause a range of physiological changes which have the potential to modulate blood pressure. Clinical trials have shown variable effects of phosphodiesterase inhibitors in humans on systemic arterial blood pressure, with most trials finding little or no effect [15]. However, trials may have been underpowered to detect such a difference.

Because of the inconsistent data in published studies, we have performed the present meta-analysis to evaluate the impact of oral pentoxifylline therapy on systemic arterial blood pressure and on pro-inflammatory cytokines, when compared with placebo in randomized clinical trials. We discuss the possible future implications of therapy using pentoxifylline as an anti-inflammatory drug.

## **METHODS**

### **Search Strategy**

This study was designed according to the guidelines of the 2009 preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement [16] and was registered in the PROSPERO database (CRD42016035988). SCOPUS



(<http://www.scopus.com>), Medline (<http://www.ncbi.nlm.nih.gov/pubmed>), and ProQuest (<http://www.proquest.com>) and EMBASE (<http://www.embase.com>) databases were searched using the following search terms in titles and abstracts (and in combination with MESH terms in Pubmed/Medline): ("blood pressure" OR systolic OR diastolic OR SBP OR DBP OR hypertension OR hypertensive OR hypotension OR hypotensive OR anti-hypertensive) AND (pentoxifylline OR oxpentifylline OR torental OR trental OR agapurin OR oxpentifylline OR PENTOX OR PENTOXIL OR FLEXITAL). The wild-card term "\*" was used to increase the sensitivity of the search strategy. No language restrictions were used in the literature search. The search was limited to studies in human. The literature was searched from inception to September 1<sup>st</sup> 2015. Two reviewers evaluated each article separately. Disagreements were resolved by agreement and discussion with a third party. The bibliographies of selected articles were hand searched to identify further relevant studies.

### **Study Selection**

Original studies were included if they met the following inclusion criteria: (i) being a randomized controlled trial with either parallel or cross-over design, (ii) investigating the impact of oral pentoxifylline on at least one of the biomarkers of systemic inflammation including serum/plasma CRP and pro-inflammatory cytokines or blood pressure iii) presenting sufficient information on baseline and end-trial concentrations (or differences) of inflammatory parameters in both pentoxifylline and control groups. Exclusion criteria were (i) non-clinical studies, (ii) uncontrolled trials, iii) trials with a treatment duration of < 2 weeks, and iv) administration of pentoxifylline in the parenteral form.

### **Data extraction**

Eligible studies were reviewed and the following data were abstracted: 1) first author's name; 2) year of publication; 3) study location; 4) inclusion criteria; 5) number of participants in the pentoxifylline and control groups; 6) age, gender and body mass index (BMI) of study participants; 7) circulating concentrations of CRP and pro-inflammatory cytokines at baseline and at the end of treatment; 8) systolic and diastolic blood pressures; and 9) prevalence of smoking, type 2 diabetes, dyslipidemia, hypertension and CHD.

### **Quality assessment**

A systematic assessment of bias in the included studies was performed using the Cochrane criteria [17]. The items used for the assessment of each study were as follows: adequacy of sequence generation, allocation concealment, blinding of subjects and personnel, blinding of outcome assessment, treatment of dropouts (incomplete outcome data), selective outcome reporting, and other potential sources of bias. According to the recommendations of the Cochrane Handbook, a judgment of “yes” indicated low risk of bias, while “no” indicated high risk of bias. Labeling an item as “unclear” indicated an unclear or unknown risk of bias.

### **Quantitative Data Synthesis**

Meta-analysis was conducted using the Comprehensive Meta-Analysis (CMA) V2 software (Biostat, NJ) [18]. Plasma concentrations of CRP and pro-inflammatory cytokines were collated in mg/L and pg/mL, respectively. Systolic and diastolic blood

pressure were recorded as mmHg. Standard deviations (SDs) of the mean difference were calculated using the following formula:  $SD = \text{square root} [(SD_{\text{pre-treatment}})^2 + (SD_{\text{post-treatment}})^2 - (2R \times SD_{\text{pre-treatment}} \times SD_{\text{post-treatment}})]$ , assuming a correlation coefficient ( $R$ ) = 0.5. When studies reported SEM, SD was estimated using the following formula:  $SD = SEM \times \text{sqrt}(n)$ , where  $n$  is the number of subjects.

Net changes in measurements (change scores) were calculated for parallel trials, as follows: (measure at end of follow-up in the treatment group – measure at baseline in the treatment group) – (measure at end of follow-up in the control group – measure at baseline in the control group). A random-effects model and the generic inverse variance method were used to compensate for the heterogeneity of studies in terms of design, pentoxifylline dose, duration of treatment, and demographic characteristics of individual trials (underlying disease, age, gender and etc). In order to avoid double-counting of subjects and consequent unit-of-analysis error the trials with more than 1 treatment arm, the control group was evenly (where possible) divided into appropriate subgroups. Effect size was expressed as weighed mean difference (WMD) and 95% confidence interval (CI). In order to evaluate the influence of each study on the overall effect size, sensitivity analysis was conducted using the leave-one-out method (i.e. removing one study each time and repeating the analysis).

### **Meta-regression**

Random-effects meta-regression was performed using unrestricted maximum likelihood method to evaluate the association between calculated WMD in plasma concentrations of inflammatory factors with dose and duration of treatment with pentoxifylline.

## **Publication bias**

Potential publication bias was explored using visual inspection of Begg's funnel plot asymmetry, and Begg's rank correlation and Egger's weighted regression tests. Duval & Tweedie "trim and fill" method was used to adjust the analysis for the effects of publication bias [19].

## **RESULTS**

### **Search results and trial flow**

The searches uncovered 314 articles. The initial screening for potential relevance removed 295 articles in whose titles and/or abstracts were obviously irrelevant. Among the 19 full text articles assessed for eligibility, 4 papers were excluded for the following reasons: non-clinical studies ( $n=1$ ), uncontrolled trials ( $n=1$ ), trials with a treatment duration of  $< 2$  weeks ( $n=1$ ), administration of pentoxifylline in the parenteral form ( $n=1$ ) (**Figure 1**).

### **Characteristics of included studies**

After assessment, 15 RCTs achieved the inclusion criteria and were used for the final meta-analysis [20-34] and these reported 18 treatment arms. A total of 739 individuals participated in the selected trials and 377 of them were allocated to the pentoxifylline group and 362 subjects to control group. The number of participants in these trials ranged from 23 to 100. Included studies were published between 1998 and 2015, and were conducted in South Africa (3 studies), USA (3 studies), Spain (2 studies), Germany, India, Brazil, Turkey, Iran, and Egypt. All the studies used 400 or

600 mg pentoxifylline tablets and the doses ranged from 400 mg/day to 1200 mg/day. Duration of treatment with pentoxifylline ranged between 1 month and 12 months. All trials were designed as parallel-group studies. Baseline and demographic characteristics of included studies are summarized in **Table 1**.

### **Quality assessment**

Some of the studies included reported insufficient information about the random sequence generation and allocation concealment. The majority of selected studies were double-blind, although five trials [21, 22, 25, 27, 28] were not blinded. Details of the quality assessment are shown in **Table 2**.

### **Quantitative data synthesis**

Overall, the impact of pentoxifylline treatment on plasma concentrations of TNF- $\alpha$  [20, 22, 25, 28, 30-34], CRP [21, 25-27, 32] and IL-6 [20, 23, 26, 33] was reported in 11, 5 and 5 treatment arms, respectively. Meta-analysis showed a significant effect of pentoxifylline treatment in reducing plasma concentrations of TNF- $\alpha$  (WMD: -1.03 pg/mL, 95% CI: -1.54, -0.51,  $p < 0.001$ ) (**Figure 2**) and CRP (WMD: -1.39 mg/L, 95% CI: -2.68, -0.10,  $p = 0.034$ ) (**Figure 3**). However, no significant alteration was observed in plasma IL-6 concentrations following pentoxifylline treatment (WMD: 1.17 pg/mL, 95% CI: -1.28, 3.62,  $p = 0.350$ ) (**Figure 4**). The meta-analyses on changes in plasma TNF- $\alpha$  and IL-6 concentrations were robust in the leave-one-out sensitivity analysis; however, the meta-analysis of CRP concentrations was sensitive to studies by Maiti *et al.*[27], Sliwa *et al.* [32], Demir *et al.*[21] and Goicochea *et al.* [25] (**Figure 3, lower panel**).

Meta-analysis of 9 RCTs (10 treatment arms) [20, 21, 24, 25, 28-32] did not suggest any significant effect of pentoxifylline on SBP (WMD: 0.82 mmHg, 95% CI: -1.70, 3.34,  $p = 0.523$ ) (**Figure 5**). Meta-analysis of 8 RCTs (9 treatment arms) [20, 21, 24, 25, 28, 29, 31, 32] did not suggest any significant effect of pentoxifylline on DBP (WMD: 0.09 mmHg, 95% CI: -1.29, 1.47,  $p = 0.895$ ) (**Figure 6**). Both analyses (SBP and DBP) were robust in the leave-one-out sensitivity analysis (**Figures 5 and 6, lower plots**). Because the trial conducted by Goicochea *et al.* [25] was the only trial to report the change in BP after pentoxifylline treatment in a hypertensive population (Mean SBP >140 mmHg), we repeated this analysis with the data from Goicochea *et al.* excluded. Thus, the effects of pentoxifylline treatment on a population which were normal as baseline was as follows: SBP: WMD = 0.91; 95% = -1.90, 3.72;  $p = 0.524$ ; DBP: WMD = 0.27; 95% = -1.15, 1.69;  $p = 0.708$  (**Figures 5 and 6, lower plots**).

### Meta-regression

Meta-regression analysis was conducted to evaluate the association between changes in plasma TNF- $\alpha$  concentrations and potential confounder variables including dose and duration of treatment with pentoxifylline. The impact of pentoxifylline on plasma TNF- $\alpha$  levels was found to be positively associated with treatment duration (slope: 0.031; 95% CI: 0.004, 0.057;  $p = 0.023$ ) but independent of pentoxifylline dose (slope: -0.0003; 95% CI: -0.002, 0.001;  $p = 0.687$ ) (**Figure 7**).

### Publication bias

Visual inspection of the funnel plot of the study precision (inverse SEM) by effect size (mean difference) suggested an asymmetry in the meta-analysis of the effect of pentoxifylline on plasma TNF- $\alpha$  concentration that was addressed by the imputation of 3 studies on the right side of the mean using trim-and-fill method. The imputed effect size was -0.95 pg/mL (95% CI: -1.45, -0.45), showing a significant effect after imputation of potentially missing studies. There was no sign of publication bias according to either Begg's rank correlation (Kendall's Tau with continuity correction = -0.11,  $z = 0.47$ , two-tailed  $p$ -value = 0.640) and Egger's linear regression (intercept = 0.05, 95% CI = -1.18, 1.29,  $t = 0.096$ ,  $df = 9.00$ , two-tailed  $p = 0.926$ ) test. Funnel plot of the impact of pentoxifylline treatment on plasma TNF- $\alpha$  concentration is illustrated in **Figure 8**.

## DISCUSSION

Our meta-analysis showed that pentoxifylline treatment was associated with a statistically significant reduction in the concentrations of TNF- $\alpha$  and CRP in plasma. However, no significant alteration of plasma IL-6 concentrations was observed following pentoxifylline treatment.

Four studies investigated the effect of pentoxifylline in patients with dilated cardiomyopathy with various causes (ischemic etiology in Sliwa et al. 2004 and Bahrman et al. 2004; idiopathic in Sliwa et al. 1998, Skudicky et al. 2001 and Bahrman et al. 2004, hypertensive in Bahrman et al. 2004) [20, 30-32]. Sliwa et al. 1998 investigated the effect of pentoxifylline on left ventricular performance in idiopathic dilated cardiomyopathy and concluded that pentoxifylline treatment reduced the concentration of TNF- $\alpha$  in plasma and was associated with improvement of

symptoms and left ventricular systolic function [31]. This was in contrast to the studies performed by Skudicky et al. 2001 [30] and Bahrmann et al. 2004 [20] which included patients with idiopathic cardiomyopathy. In these studies, treatment with pentoxifylline was not associated with significant changes in TNF-alpha [20, 30] and IL-6 [20] concentrations. Significant improvements in symptoms and left ventricular function were seen in one trial [30] but not the other [20]. However in this negative study, the results are complicated by the fact patients in this study were treated with a beta-blocker (carvedilol) for the 3 months prior to initiation of pentoxifylline therapy. Functional improvement by beta-blockers in heart failure is well documented as well as the potential of these drugs to reduce concentrations of circulating inflammatory cytokines [35]. Thus a 'ceiling' beneficial effect may have been reached before pentoxifylline treatment began.

In patients with ischemic cardiomyopathy, adding pentoxifylline to standard therapy (which included beta blockers) was associated with reduction in plasma concentration of inflammatory markers TNF-alpha and CRP, marker of apoptosis (Fas/Apo-1) and correlated with improvement of left ventricular ejection fraction [32].

Three studies investigated the effect of pentoxifylline in patients with non-alcoholic steatohepatitis (NASH) [22, 33, 34]. In studies conducted by Van Wagner et al. 2011 [33] and Zein et al. 2011 [34], pentoxifylline treatment did not alter serum TNF- $\alpha$ , concentrations, but improved liver enzymes and histology in patients with NASH, but did not appear to offer substantial benefit over placebo [33] with some benefit in liver fibrosis at one year [34]. But pentoxifylline therapy reduced hepatic



expression of collagen-1, an important fibrogenic gene, and TIMP-1, which is also involved in fibrosis, however the latter effect was not statistically significant. Thus pentoxifylline could have potential benefit on fibrosis. Both studies concluded that pentoxifylline treatment is well tolerated [33, 34]. When pentoxifylline was added to fenofibrate treatment in patients with NASH (El-Haggar et al. 2015) [22], patients receiving both drugs showed significantly lower TNF- $\alpha$  concentrations than that detected with fenofibrate treated group. The author concluded that the combination of pentoxifylline and fenofibrate has a beneficial effect on liver markers of fibrosis, liver stiffness, insulin resistance and inflammatory pathways implicated in NASH [22].

Two studies investigated the anti-inflammatory effect of pentoxifylline in patients with type 2 diabetes mellitus. In study conducted by Navarro et al in 2005, pentoxifylline therapy was added to angiotensin II receptor blocker (ARB) therapy in normotensive patients with diabetes and residual albuminuria despite adequate therapy with an ARB [28]. The study showed that pentoxifylline added to ARB therapy was associated with a significant reduction of concentrations of TNF- $\alpha$  in serum and urine. This modulation of inflammatory responses could explain the supplementary antiproteinuric effect observed [28]. It has also been demonstrated that in hypertensive patients with type 2 diabetes mellitus pentoxifylline treatment improved inflammatory markers, oxidative stress and platelet-aggregation. In this trial, however, hsCRP was used as a marker for inflammation and TNF- $\alpha$  was not reported. [27]

In patients with coronary artery disease, pentoxifylline treatment has been shown to be associated with a statistically significant reduction in pro-inflammatory response (decreased CRP and TNF- $\alpha$ ) and a trend towards increased concentrations of

the anti-inflammatory mediator TGF-beta1. Although this study was small and did not measure clinical events, it nevertheless showed an anti-inflammatory effect of pentoxifylline treatment [23].

The mechanisms by which phosphodiesterase inhibitors such as pentoxifylline can elicit anti-inflammatory effects have been comprehensively reviewed elsewhere [36, 37]. In particular, the inhibition of the isozyme phosphodiesterase-4 is likely to be important. Phosphodiesterase 4 highly expressed in inflammatory cells including neutrophils, macrophages, T cells and endothelial cells [38]. Insights from the respiratory system have shown that inhibition of phosphodiesterase 4 in immune cells and the subsequent elevation of cAMP results in an anti-inflammatory effect [38-40]. Specific inhibitors of this isoenzyme are being developed for use in the treatment of a wide range of disease states with an inflammatory component, including dermatological, neurological and respiratory conditions [38, 41-46]. With respect to the reduction in TNF- $\alpha$  by pentoxifylline observed in this study, Shaw [11] has comprehensively reviewed the potential mechanisms which include: Suppression of TNF- $\alpha$  gene transcription by pentoxifylline [47], attenuation of the response of TNF- $\alpha$  to endotoxin [48], and attenuation of Interleukin-2, a cytokine which stimulates TNF- $\alpha$  production [6],

Primarily used to treat peripheral arterial disease patients due to the improved circulation obtained through its ability to alter erythrocyte deformability, pentoxifylline also enhances capillary microcirculation [2, 11]. We examined the potential of this methylxanthine derivate as a blood pressure (BP) lowering agent in a range of studies, including those that reported its effects in hypertensive patients [20, 27] . Blood

pressure was similar in pentoxifylline and control groups and no significant differences were observed during the follow-up period in systolic blood pressure or diastolic blood pressure.

The lack of effect of pentoxifylline on systemic arterial blood pressure seen in this study supports previous observations with pentoxifylline [49] and other phosphodiesterase inhibitors [15] where little or no effect on blood pressure was observed. It is important to note that in all but one of the studies which measured the effect of pentoxifylline on blood pressure, the participants were normotensive at baseline. It would be difficult to demonstrate a hypotensive effect of a drug in such a population. Nevertheless, the study performed by Goicochea *et al.*[25] which enrolled a hypertensive population (mean SBP >140 mmHg) did not demonstrate an effect of pentoxifylline on BP, and exclusion of this study from the meta-analysis did not affect the result. The ubiquity of cAMP (and cGMP) signaling, modulated by phosphodiesterases, results in multiple and complex physiological effects when these enzymes are inhibited. In the vasculature, the accumulation of cAMP promotes vasodilation and a reduction in peripheral resistance [50, 51] which would be expected to be associated with a hypotensive effect. However, the dose required for this effect may be higher than the usual clinical dose [52]. Conversely, in the myocardium, phosphodiesterase inhibition and elevation of cAMP have been shown to elicit positive chronotropic [53] and inotropic [54] responses which would be expected to increase blood pressure. Thus the effects of pentoxifylline in the heart and the vasculature would appear to have small, functionally opposite effects on blood pressure, and the overall effect would appear to be a 'zero sum'. An antihypertensive effect of pentoxifylline would be desirable in the treatment of cardiovascular disease.

However, the fact that no pressor effect of pentoxifylline has been demonstrated, means that it can be used for its anti-inflammatory effects without concerns about an adverse effect on blood pressure. Further investigations into the effects of this drug on blood pressure in a hypertensive population are warranted.

The present meta-analysis has several limitations. Most importantly, there were only a small number of eligible RCTs and most of them included relatively small populations. Furthermore, these studies were heterogeneous regarding population characteristics, study design, and pathology of patients involved. A conservative random-effects model was used to account for the heterogeneity between the studies and sensitivity analysis was performed to examine the impact of each individual study on the overall effect size.

### **Conclusion**

In conclusion, our meta-analysis has shown a significant anti-inflammatory effect of pentoxifylline treatment, exemplified by reduced concentrations of TNF- $\alpha$  and CRP in plasma in a range pathologies including coronary artery disease, type 2 diabetes mellitus, idiopathic and ischemic cardiomyopathy and chronic kidney disease. Pentoxifylline treatment was associated with anti-inflammatory effects when given alone or when added to standard therapy. This is not a licensed indication for pentoxifylline. We did not detect any effect of pentoxifylline on Il-6 or systemic arterial blood pressure. None of the randomized controlled trials (RCT) gave any cause to doubt the safety of pentoxifylline treatment. This raises the possibility that pentoxifylline may have therapeutic benefit in diseases where inflammatory pathways (characterized by

elevated by TNF- $\alpha$  and CRP) play an important role. These may include rheumatoid arthritis, asthma and atherosclerotic cardiovascular disease. Further outcomes- based RCTs are warranted to test the effect of pentoxifylline in such circumstances.

## References

1. Salhiyyah K, Senanayake E, Abdel-Hadi M, Booth A, Michaels JA. Pentoxifylline for intermittent claudication. The Cochrane database of systematic reviews. 2012; 1:Cd005262.
2. Zhang M, Xu YJ, Mengi SA, Arneja AS, Dhalla NS. Therapeutic potentials of pentoxifylline for treatment of cardiovascular diseases. *Exp Clin Cardiol*. 2004; 9 (2):103-11.
3. Ward A, Clissold SP. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. *Drugs*. 1987; 34 (1):50-97.
4. Aviado DM, Porter JM. Pentoxifylline: a new drug for the treatment of intermittent claudication. Mechanism of action, pharmacokinetics, clinical efficacy and adverse effects. *Pharmacotherapy*. 1984; 4 (6):297-307.
5. D'Hellencourt CL, Diaw L, Cornillet P, Guenounou M. Differential regulation of TNF $\alpha$ , IL-1 $\beta$ , IL-6, IL-8, TNF $\beta$ , and IL-10 by pentoxifylline. *International Journal of Immunopharmacology*. 1996; 18 (12):739-48.
6. Marcinkiewicz J, Grabowska A, Lauterbach R, Bobek M. Differential effects of pentoxifylline, a non-specific phosphodiesterase inhibitor, on the production of IL-10, IL-12 p40 and p35 subunits by murine peritoneal macrophages. *Immunopharmacology*. 2000; 49 (3):335-43.
7. Dinarello CA. Proinflammatory cytokines. *Chest*. 2000; 118 (2):503-8.
8. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. *New England Journal of Medicine*. 2000; 342 (12):836-43.
9. Koenig W, Sund M, Fröhlich M, Fischer HG, Löwel H, Döring A, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (monitoring trends and determinants in cardiovascular disease) Augsburg cohort study, 1984 to 1992. *Circulation*. 1999; 99 (2):237-42.

10. Back M, Hansson GK. Anti-inflammatory therapies for atherosclerosis. *Nat Rev Cardiol.* 2015; 12 (4):199-211.
11. Shaw SM, Shah MK, Williams SG, Fildes JE. Immunological mechanisms of pentoxifylline in chronic heart failure. *European journal of heart failure.* 2009; 11 (2):113-8.
12. Reed WR, DeGowin RL. Suppressive effects of pentoxifylline on natural killer cell activity. *J Lab Clin Med.* 1992; 119 (6):763-71.
13. Zabel P, Schade FU, Schlaak M. Inhibition of endogenous TNF formation by pentoxifylline. *Immunobiology.* 1993; 187 (3–5):447-63.
14. Poulakis N, Androutsos G, Kazi D, Bastas A, Provata A, Bitsakou C, et al. The differential effect of pentoxifylline on cytokine production by alveolar macrophages and its clinical implications. *Respiratory Medicine.* 1999; 93 (1):52-7.
15. Feneck R. Phosphodiesterase inhibitors and the cardiovascular system. *Continuing Education in Anaesthesia, Critical Care & Pain.* 2007; 7 (6):203-7.
16. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Bmj.* 2009; 339:b2535.
17. Green S. *Cochrane handbook for systematic reviews of interventions version 5.1.0* [updated March 2011]. The Cochrane Collaboration. 2011.
18. Borenstein M, Hedges L, Higgins J, Rothstein H. *Comprehensive meta-analysis version 2.* Englewood, NJ: Biostat. 2005; 104.
19. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. *Biometrics.* 2000; 56 (2):455-63.
20. Bahrmann P, Hengst UM, Richartz BM, Figulla HR. Pentoxifylline in ischemic, hypertensive and idiopathic-dilated cardiomyopathy: effects on left-ventricular function, inflammatory cytokines and symptoms. *European journal of heart failure.* 2004; 6 (2):195-201.

21. Demir E, Paydas S, Balal M, Kurt C, Sertdemir Y, Erken U. Effects of pentoxifylline on the cytokines that may play a role in rejection and resistive index in renal transplant recipients. *Transplant Proc.* 2006; 38 (9):2883-6.
22. El-Haggar SM, Mostafa TM. Comparative clinical study between the effect of fenofibrate alone and its combination with pentoxifylline on biochemical parameters and liver stiffness in patients with non-alcoholic fatty liver disease. *Hepatology international.* 2015; 9 (3):471-9.
23. Fernandes JL, de Oliveira RT, Mamoni RL, Coelho OR, Nicolau JC, Blotta MH, et al. Pentoxifylline reduces pro-inflammatory and increases anti-inflammatory activity in patients with coronary artery disease--a randomized placebo-controlled study. *Atherosclerosis.* 2008; 196 (1):434-42.
24. Ghorbani A, Omidvar B, Beladi-Mousavi SS, Lak E, Vaziri S. The effect of pentoxifylline on reduction of proteinuria among patients with type 2 diabetes under blockade of angiotensin system: a double blind and randomized clinical trial. *Nefrologia.* 2012; 32 (6):790-6.
25. Goicoechea M, Garcia de Vinuesa S, Quiroga B, Verdalles U, Barraca D, Yuste C, et al. Effects of pentoxifylline on inflammatory parameters in chronic kidney disease patients: a randomized trial. *J Nephrol.* 2012; 25 (6):969-75.
26. Gupta SK, Mi D, Dube MP, Saha CK, Johnson RM, Stein JH, et al. Pentoxifylline, inflammation, and endothelial function in HIV-infected persons: a randomized, placebo-controlled trial. *PLoS One.* 2013; 8 (4):e60852.
27. Maiti R, Agrawal NK, Dash D, Pandey BL. Effect of Pentoxifylline on inflammatory burden, oxidative stress and platelet aggregability in hypertensive type 2 diabetes mellitus patients. *Vascular pharmacology.* 2007; 47 (2-3):118-24.
28. Navarro JF, Mora C, Muros M, Garcia J. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-



term, randomized, controlled trial. *Journal of the American Society of Nephrology : JASN*.

2005; 16 (7):2119-26.

29. Shahidi S, Hoseinbalam M, Iraj B, Akbari M. Effect of pentoxifylline on microalbuminuria in diabetic patients: a randomized controlled trial. *Int J Nephrol*. 2015; 2015:259592.

30. Skudicky D, Bergemann A, Sliwa K, Candy G, Sareli P. Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol: results of a randomized study. *Circulation*. 2001; 103 (8):1083-8.

31. Sliwa K, Skudicky D, Candy G, Wisenbaugh T, Sareli P. Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy. *Lancet (London, England)*. 1998; 351 (9109):1091-3.

32. Sliwa K, Woodiwiss A, Kone VN, Candy G, Badenhorst D, Norton G, et al. Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study. *Circulation*. 2004; 109 (6):750-5.

33. Van Wagner LB, Koppe SW, Brunt EM, Gottstein J, Gardikiotes K, Green RM, et al. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. *Annals of hepatology*. 2011; 10 (3):277-86.

34. Zein CO, Yerian LM, Gogate P, Lopez R, Kirwan JP, Feldstein AE, et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. *Hepatology*. 2011; 54 (5):1610-9.

35. Prabhu SD, Chandrasekar B, Murray DR, Freeman GL. beta-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. *Circulation*. 2000; 101 (17):2103-9.

36. Page CP, Spina D. Phosphodiesterase inhibitors in the treatment of inflammatory diseases. *Handbook of experimental pharmacology*. 2011; (204):391-414.

37. Martinez A, Gil C. cAMP-specific phosphodiesterase inhibitors: promising drugs for inflammatory and neurological diseases. *Expert opinion on therapeutic patents*. 2014; 24 (12):1311-21.
38. Chong J, Leung B, Poole P. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. *The Cochrane database of systematic reviews*. 2013; 11:Cd002309.
39. Boswell-Smith V, Spina D. PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast. *Int J Chron Obstruct Pulmon Dis*. 2007; 2 (2):121-9.
40. Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. *Am J Respir Crit Care Med*. 1998; 157 (2):351-70.
41. Moustafa F, Feldman SR. A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology. *Dermatology online journal*. 2014; 20 (5):22608.
42. Eskandari N, Mirmosayyeb O, Bordbari G, Bastan R, Yousefi Z, Andalib A. A short review on structure and role of cyclic-3',5'-adenosine monophosphate-specific phosphodiesterase 4 as a treatment tool. *Journal of research in pharmacy practice*. 2015; 4 (4):175-81.
43. Gurney ME, D'Amato EC, Burgin AB. Phosphodiesterase-4 (PDE4) molecular pharmacology and Alzheimer's disease. *Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics*. 2015; 12 (1):49-56.
44. Hansen RT, 3rd, Zhang HT. Phosphodiesterase-4 modulation as a potential therapeutic for cognitive loss in pathological and non-pathological aging: possibilities and pitfalls. *Current pharmaceutical design*. 2015; 21 (3):291-302.
45. Mazur M, Karczewski J, Lodyga M, Zaba R, Adamski Z. Inhibitors of phosphodiesterase 4 (PDE 4): A new therapeutic option in the treatment of psoriasis vulgaris and psoriatic arthritis. *The Journal of dermatological treatment*. 2015; 26 (4):326-8.

46. Wen RT, Feng WY, Liang JH, Zhang HT. Role of phosphodiesterase 4-mediated cyclic AMP signaling in pharmacotherapy for substance dependence. *Current pharmaceutical design*. 2015; 21 (3):355-64.
47. Doherty GM, Jensen JC, Alexander HR, Buresh CM, Norton JA. Pentoxifylline suppression of tumor necrosis factor gene transcription. *Surgery*. 1991; 110 (2):192-8.
48. Zabel P, Wolter DT, Schonharting MM, Schade UF. Oxpentifylline in endotoxaemia. *Lancet (London, England)*. 1989; 2 (8678-8679):1474-7.
49. Navarro-Gonzalez JF, Mora-Fernandez C, Muros de Fuentes M, Chahin J, Mendez ML, Gallego E, et al. Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial. *Journal of the American Society of Nephrology : JASN*. 2015; 26 (1):220-9.
50. Dinn RF, Yang HT, Terjung RL. The influence of pentoxifylline and torbafylline on muscle blood flow in animals with peripheral arterial insufficiency. *J Clin Pharmacol*. 1990; 30 (8):704-10.
51. Hoeffner U, Aarhus LL, Katusic ZS, Vanhoutte PM. Pharmacology of pentoxifylline in isolated canine arteries and veins. *J Cardiovasc Pharmacol*. 1989; 14 (6):899-907.
52. Kamphuis J, Smits P, Thien T. Vascular effects of pentoxifylline in humans. *J Cardiovasc Pharmacol*. 1994; 24 (4):648-54.
53. Watanabe H, Furukawa Y, Chiba S. Cardiovascular effects of aminophylline and pentoxifylline on intact dogs and isolated dog atria. *Jpn Heart J*. 1982; 23 (2):235-43.
54. Osadchii O, Norton G, Woodiwiss A. Inotropic responses to phosphodiesterase inhibitors in cardiac hypertrophy in rats. *Eur J Pharmacol*. 2005; 514 (2-3):201-8.

**Table 1.** Baseline and demographic characteristics of the included studies

Study	Bahrmann et al <sup>s</sup>	Demi r et al.	El-Haggaret al	Fernandes et al	Ghorbani et al.	Goicoechea et al	Gupta et al	Maiti et al	Navarro et al	Shahidi et al.	Skudicky et al	Sliwa et al	Sliwa et al.	Van Wagner et al	Zein et al
Reference	[20]	[21]	[22]	[23]	[24]	[25]	[26]	[27]	[28]	[29]	[30]	[31]	[32]	[33]	[34]
Year	2004	2006	2015	2008	2012	2012	2013	2007	2005	2015	2001	1998	2004	2011	2011
Location	Germany	Turkey	Egypt	Brazil	Iran	Spain	USA	India	Spain	Iran	South Africa	South Africa	South Africa	USA	USA
Design	Double-blind randomized placebo controlled trial	Randomized controlled trial.	Randomized controlled trial.	Double-blind randomized placebo controlled trial	Double-blind randomized controlled trial	Randomized placebo controlled trial	Double-blind randomized placebo controlled trial	Randomized open add-on clinical trial	Randomized placebo controlled trial	Randomized parallel-blind group randomized	Double-blind randomized placebo controlled trial	Double-blind randomized placebo controlled trial	Double-blind randomized placebo controlled trial	Double-blind randomized placebo controlled trial	Double-blind randomized placebo controlled trial

					olled trial			olled trial	trial with parall el contr ols		contr olled trial				olled trial	olled trial
Exper iment al group s	Ca se	Usual treatme nt + pentoxi fylline	Usual treat ment + pento xifylli ne	Usual treatm ent + pentox ifylline	Usual treat ment + pento xifylli ne	Usual treatm ent + pento xifylli ne	Usual treatm ent + pentox ifyllin e	pento xifylli ne	Usual treat ment + pento xifylli ne	Usual treatm ent + pento xifylli ne	Usual treat ment + pento xifylli ne	Usual treatme nt + pentoxi fylline	Usual treatme nt + pentoxi fylline	Usual treatme nt + pentoxi fylline	Usual treat ment + pento xifylli ne	Usual treat ment + pento xifylli ne
	Co ntr ol	Usual treatme nt + Placeb o	Usual treat ment only	Usual treatm ent only	Usual treat ment + Place	Usual treatm ent only	Usual treatm ent only	Place bo	Usual treat ment only	Usual treatm ent only	Usual treat ment + Place	Usual treatme nt + Placebo	Usual treatme nt + Placebo	Usual treatme nt + Placebo	Usual treat ment + Place	Usual treat ment + Place

					bo						bo				bo	bo
Durati on of trial	6 months	3 mont hs	6 months	6 mont hs	6 month s	12 month s	2 mont hs	1 mont h	4 month s	6 mont hs	6 months	6 months	6 months	6 months	12 mont hs	12 mont hs
Inclus ion criteri a	(1) age betwee n 18 and 70 years, (2) stable New York Heart Associ ation (NYH A) class	(1)Pat ients who had receiv ed a renal transp lant from a living donor more than	Patient s who had persist ently abnor mal aminot ransfer ase levels in two separat e occasi	Patie nts betwe en 18 and 80 years with non- ST- segm ent elevat ion ACS,	Patien ts with type 2 diabet es mellit us and diabet ic nephr opath y (persi stent	(1) presen ce of CKD, define d as an estima ted glome rular filtrati on rate (eGFR	HIV- infect ed partic ipants not on ART. b	Patie nts with type 2 diabet es mellit us with hyper tensio n aged 45	Diabet ic nephr opath y, define d by persist ent album inuria >300 mg/24 h in two	Patien ts aged >18 years. GFR > 60 ml/mi n/1.7 3 m <sup>2</sup> . Blood press ure <140/ 90	(1) age age ≥18 and ≤70 years, (2) stable NYHA functio nal class II or III ) congest ive heart	age betwee n 18 and 70 years; stable New York Heart Associa tion (NYHA ) functio nal class	(1) age≥ 18 and ≤70 years; (2) stable New York Heart Associa tion (NYHA ) functio nal class	Subje cts betwe en the ages of 18 and 65 witho ut evide nce of other liver diseas	(1) daily alcoh ol intake of <30 g for males and <15 g for femal es; (2)	

		II or III CHF due to ischemi c and hyperte nsive cardio myopat hy or idiopat hic- dilated cardio myopat hy, (3) left ventric	6 mont hs befor e recrui tment . (2) Symp tom- free (3) Seru m creati nine levels < 1.8 mg/dl	ons over the past six months . (2) Sympt om- free (3) Seru m creati nine levels < 1.8 mg/dl	elevat ed cardia c mark ers (defin ed as tropo nin I > 0.1 ng/m L) and at least one other high- risk	protei nuria > 150m g/24h r in 3 conse cutive measu remen ts. No other kidne y or renal tract diseas	) lower than 60 ml/mi n per 1.73 m <sup>2</sup> , (2) stable clinica l condit ion define d as no hospit alizati		years and older; the patien ts were free from other signif icant morbi dity speci ally infect ion, infest	conse cutive deter minati ons, no other kidne y or renal tract diseas e, and presen ce of diabet ic retino pathy	mmH g (using beta- block ers, ARBs or ACEI , on a diet with protei n intake < 0.8 g/Kg/ d, HbA1	failure of unknow n cause, (3) LV ejection fraction (LVEF) < 40% by radionu clide angiogr aphy, (4) sinus rhythm, and (5)	class II or III congest ive heart failure seconda ry to coronar y artery disease, as defined by the presenc e of $\geq$ 2- vessel disease on angiogr	II or III congest ive heart failure seconda ry to coronar y artery disease, as defined by the presenc e of $\geq$ 2- vessel disease on angiogr	e and an initial biops y evalu ation (withi n 6 mont hs of entry) with steato hepati tis define d by the	appro priate exclu sion of other liver diseas es; (3) age betwe en 18 and 70 years and (4) the
--	--	--	---	--	--	---	---	--	---	--	---	---	---	--	--	--

		ular ejection fraction (LVEF ) less or equal than 40% assesse d by contras t 2D echocar diograp hy and (4) sinus			criteri a: an episo de of angin a at rest lastin g longe r than 20 min in the prece ding 24 h; rest	e. Insuff icient respo nse to adequ ate therap y with losart an and enalap ril in at least 3 month s	ons or cardio vascul ar events within the 3 month s before screen ing, (3) stable renal functi on (baseli ne		ations , infla mmat ory or neopl astic diseas es.	and norma l BP ( $\leq 140/$ 90 mmH g); treatm ent with the recom mende d doses of ARB for >1 yr;	c < 8%, spot urine album in- creati nine ratio < 300 mg/g in 3 conse cutive meas ureme nts over 3	eligible patients in whom high- quality echocar diograp hic images could be obtaine d. echocar diograp hic images.	ed by radionu clide angiogr aphy; sinus rhythm; and possibil ity of obtaini ng high- quality echocar diograp hic images.	aphy; (3) left ventric ular ejection fraction < 40% by radionu clide scintigr aphy; (4) sinus rhythm; and (5) eligible patients	prese nce of steato sis, infla mmat ion and balloo ning.	abilit y to give infor med conse nt. Patie nts with diabet es mellit us type 2 (DM) were inclu
--	--	---	--	--	---	---	--	--	---	---	---	---	---	---	---	--



		rhythm			angin a with dyna mic ST chang es ≥0.1 mV; angin a with hypot ensio n, pulm onary edem	before recruit ment.	serum creatin ine had to have not increa sed by 50% in the 3 month s before screen ing) and (4) no chang			norma l renal functi on, define d as a GFR ≥90 ml/mi n (calcu lated using the Modif icatio n of Diet in	mont hs.			in whom high- quality echocar diograp hic images could be obtaine d.	ded only if their thera peutic regim en was limite d to oral agent s inclu ding sulfo nylur eas
--	--	--------	--	--	--	----------------------------	--	--	--	---	-------------	--	--	---	---

					<p>a or ventri cular tachy cardia or a TIMI score ≥5.</p>		<p>es in conco mitant medic ation during the study.</p>			<p>Renal Diseas e study equati on) ; and insuffi cient respon se to conve ntiona l therap y, define d as album</p>						<p>(e.g. glipiz ide and glybu ride) and/o r bigua nides (e.g. metfo rmin) , was stable (defin ed by no chang</p>
--	--	--	--	--	---	--	---	--	--	--	--	--	--	--	--	--

										inuria >400 mg/24 h in three conse cutive measu remen ts in the 3 month sbefore e includi on in the study.						es in oral agent s or their dose for at least 6 mont hs), and with relati vely adequ ate gluco se
--	--	--	--	--	--	--	--	--	--	---	--	--	--	--	--	---

																control as defined by HgbA1C < 8%.
Pentoxifylline intervention		1200 mg daily	1200 mg daily	1200 mg daily	1200 mg daily	400 mg daily	800 mg/day	1200 mg daily	800 mg/day	1200 mg/day	1200 mg/day	1200 mg daily	1200 mg daily	1200 mg daily	1200 mg daily	1200 mg daily
Participants	Case	21	22	45	29	50	34	10	25	30	20	16	14	19	19	23
	Control	20	20	45	28	50	36	13	26	31	20	16	10	14	7	26
Age	Ca	55±12	33±1	45.3±5	60.6±	56±7.	NR	40±1	56.37	58.6±	50.3±	50±9	49.1±8	57±10	48±2	50.5±

(years )	se		2	.34	1.7	6		1.6	6±8.6	9.0	9					12.7
	Control	58±12	35±1 2	43.78± 6.30	60.9± 1.7	58±8. 0	NR	34±1 0.9	53.81 ±7.21	58.8± 6.0	10.7	55.6±	47±12	55.7±1 2	53±11	53±2
Male (%)	Cause	87	64	71.11	63	56	NR	62	50	53.34	40.9	50	50	75	38	69
	Control	100	70	66.67	69	52	NR	85	66.67	48.38	33.3	86	85.7	67	62	69.2
BMI Kg/m <sup>2</sup> )	Cause	28±3	NR	27.14 ± 1.27	27.5± 0.7	32.06	NR	NR	26.45 ±4.25	NR	30.51 ±7.13	NR	NR	NR	34.0 ± 0.9	32.9 ± 4.6
	Control	28±5	NR	27.26 ± 1.06	27.8± 0.8	31.84	NR	NR	25.19 ±3.01	NR	30.75 ±4.22	NR	NR	NR	35.1 ± 2.6	34.0 ± 5.4

	ol															
SBP (mm Hg)	Ca	125± 12	127 ± 9.2	NR	NR	122.2	148 ± 24	NR	144.5 ±12.9 5	134.4 ± 6.0	115.6 8±11. 16	120± 18	121	119±19	NR	NR
	Co ntr ol	118± 13	128 ± 8.4	NR	NR	124.4	147 ± 16	NR	139.5 5±10. 39	132.1 ± 6.2	115.2 8±9.1 5	111± 22	115	117±18	NR	NR
DBP (mm Hg)	Ca	77± 9	84 ± 3.9	NR	NR	72.3	77 ± 15	NR	86.0± 7.70	83.3± 6.7	75.45 ±8.15	76 ±11	73	77±14	NR	NR
	Co ntr ol	73± 10	85 ± 4.1	NR	NR	74.6	76± 13	NR	82.71 ±6.35	81.5 ±7.6	77.29 ±8.26	70± 13	70	74±13	NR	NR
TNF- α pg/ml	Ca se	11± 7	4.2 ± 2.1	5.67±1 .24	2.5(3. 9) *	NR	6.6±1. 9 <sup>‡</sup>	NR	NR	6.4(2. 1 to 9.7)	NR	2.5±1.9	6.5±3.0	7.0±3.4	NR	7.4±2 .0



	Co ntr ol	7± 6	2.12 ± 0.6	NR	4.4(6. 9) *	NR	NR	1.91 (1.53) €	NR	NR	NR	NR	NR	NR	NR	NR

Values are expressed as mean  $\pm$  SD; <sup>‡</sup>-Values represent relative means  $\pm$  SEM; \*Values represent median (interquartile range); €-Values represent as means (standard deviation); <sup>‡</sup>-Data are expressed as mean  $\pm$  standard deviation or median (interquartile range); <sup>§</sup> The trial conducted by Bahrmann et al included two treatment arms which represented two populations: Group A, Patients with ischemic dilated and hypertensive cardiomyopathy; Group B: Patients with idiopathic dilated cardiomyopathy.

**Abbreviations:** ACEI-angiotensin converting enzyme inhibitor; ARB- angiotensin receptor blocker; BNP-brain natriuretic peptide; CRP- C reactive protein; GFR-glomerular filtration rate; IL-interleukin; LVEF-left ventricle ejection fraction; NR-not reported; NYHA- New York Heart Association; PAI-1- Plasminogen activator inhibitor-1; sTNFRI-soluble tumor necrosis factor receptor; TGF-tumor growth factor; TNF-tumor necrosis factor;






**Table 2** Assessment of risk of bias in the included studies using Cochrane criteria.

<b>Study</b>	<b>Ref</b>	<b>Sequence generation</b>	<b>Allocation concealment</b>	<b>Blinding of participants and personnel</b>	<b>Blinding of outcome assessment</b>	<b>Incomplete outcome data</b>	<b>Selective outcome reporting</b>	<b>Other potential threats to validity</b>
<b>Bahrman et al. 2004</b>	[20]	U	U	L	L	L	L	L
<b>Demir et al. 2006</b>	[21]	H	H	H	H	L	L	L
<b>El-Haggar et al. 2015</b>	[22]	U	U	H	H	L	L	L
<b>Fernandes 2008</b>	[23]	L	L	L	U	L	L	L
<b>Ghorbani et al. 2012</b>	[24]	L	L	U	U	L	L	L
<b>Goicoechea et al 2012</b>	[25]	L	L	H	H	L	L	L


<b>Gupta et al.2013</b>	[26]	L	L	L	L	L	L	L
<b>Navarro et al. 2005</b>	[28]	L	L	H	H	L	L	L
<b>Maiti et al. 2007</b>	[27]	U	U	H	H	L	L	L
<b>Shahidi et al. 2015</b>	[29]	L	L	L	U	L	L	L
<b>Skudicky et al. 2001</b>	[30]	U	U	L	L	L	L	L
<b>Sliwa et al. 1998</b>	[31]	L	L	L	L	L	L	L
<b>Sliwa et al. 2004</b>	[32]	L	L	L	L	L	L	L
<b>Van Wagner et al. 2011</b>	[33]	L	L	L	L	L	L	L
<b>Zein et al. 2011</b>	[34]	L	L	L	I	L	L	L

**L: low risk of bias; H: high risk of bias; U: unclear risk of bias.**


## Figures




**Figure 1.** Flow diagram of the study selection procedure.



**Figure 2.** Forest plot detailing weighted mean difference and 95% confidence intervals for the impact of pentoxifylline treatment on plasma TNF- $\alpha$  concentrations. The trial conducted by Bahrman et al included two treatment arms which represented two populations: Group A, Patients with ischemic dilated and hypertensive cardiomyopathy; Group B: Patients with idiopathic dilated cardiomyopathy.




**Figure 3.** Forest plot detailing weighted mean difference and 95% confidence intervals for the impact of pentoxifylline treatment on plasma CRP concentrations. The lower plot shows the results of leave-one-out sensitivity analysis.




**Figure 4.** Forest plot detailing weighted mean difference and 95% confidence intervals for the impact of pentoxifylline treatment on plasma IL-6 concentrations. The trial conducted by Bahrman et al included two treatment arms which represented two populations: Group A, Patients with ischemic dilated and hypertensive cardiomyopathy; Group B: Patients with idiopathic dilated cardiomyopathy.







**Figure 5.** Forest plot detailing weighted mean difference and 95% confidence intervals for the impact of pentoxifylline treatment on systolic blood pressure. The lower plot shows the results of leave-one-out sensitivity analysis. The trial conducted by Bahrman et al included two treatment arms which represented two populations: Group A, Patients with ischemic dilated and hypertensive cardiomyopathy; Group B: Patients with idiopathic dilated cardiomyopathy. N.B. The result is unaffected by the exclusion of the study by Goicoechea which included hypertensive participants.



**Figure 6.** Forest plot detailing weighted mean difference and 95% confidence intervals for the impact of pentoxifylline treatment on diastolic blood pressure. The lower plot shows the results of leave-one-out sensitivity analysis. The trial conducted by Bahrmann et al included two treatment arms which represented two populations: Group A, Patients with ischemic dilated and hypertensive cardiomyopathy; Group B: Patients with idiopathic dilated cardiomyopathy. N.B. The result is unaffected by the exclusion of the study by Goicoechea which included hypertensive participants.



**Figure 7.** Meta-regression plots of the association of mean changes in plasma TNF- $\alpha$  concentrations with dose and duration of pentoxifylline treatment. The size of each circle is inversely proportional to the variance of change.



**Figure 8.** Funnel plot detailing publication bias in the meta-analysis of the impact of pentoxifylline treatment on plasma TNF- $\alpha$  concentrations. Trim and fill method was used to impute for potentially missing studies. Open circles represent observed published studies; closed circles represent imputed unpublished studies.